Skip to main content
SleepCited
Figure 1

Description

Study enrollment and participant flow for a long-term follow-up trial of prolonged-release melatonin (PedPRM) in children and adolescents with autism spectrum disorder and insomnia. The diagram tracks participants through screening, treatment phases, and follow-up periods.

More Figures from This Paper

Efficacy outcomes showing changes in sleep parameters over the extended treatment period with pediatric prolonged-release melatonin in children with ASD. Long-term data indicate sustained improvements in sleep onset latency and total sleep time.

Figure 2

Efficacy outcomes showing changes in sleep parameters over the extended treatment period with pediatric prolonged-release melatonin in children with ASD. Long-term data indicate sustained improvements in sleep onset latency and total sleep time.

chart
Safety assessment data from the open-label extension of PedPRM treatment in pediatric patients with autism spectrum disorder. Adverse event profiles suggest the prolonged-release melatonin formulation maintained an acceptable safety profile over the extended study period.

Figure 3

Safety assessment data from the open-label extension of PedPRM treatment in pediatric patients with autism spectrum disorder. Adverse event profiles suggest the prolonged-release melatonin formulation maintained an acceptable safety profile over the extended study period.

chart
Summary of sleep quality measures or caregiver-reported outcomes during long-term PedPRM administration in children with ASD and comorbid insomnia. Results suggest continued therapeutic benefit with nightly melatonin use.

Figure 4

Summary of sleep quality measures or caregiver-reported outcomes during long-term PedPRM administration in children with ASD and comorbid insomnia. Results suggest continued therapeutic benefit with nightly melatonin use.

chart

Figure 1

Flowchart
981 × 1034px · 249.9 KB

Source Paper

Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder.

Journal of child and adolescent psychopharmacology (2018)

PMID: 30132686

DOI: 10.1089/cap.2018.0020

Cite This Figure

![Figure 1: Study enrollment and participant flow for a long-term follow-up trial of prolonged-release melatonin (PedPRM) in children and adolescents with autism spectrum disorder and insomnia. The diagram tracks participants through screening, treatment phases, and follow-up periods.](https://pdfs.citedhealth.com/figures/30132686/79.png)

> Source: Athanasios Maras et al. "Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insom." *Journal of child and adolescent psychopharmacology*, 2018. PMID: [30132686](https://pubmed.ncbi.nlm.nih.gov/30132686/)
<figure>
  <img src="https://pdfs.citedhealth.com/figures/30132686/79.png" alt="Study enrollment and participant flow for a long-term follow-up trial of prolonged-release melatonin (PedPRM) in children and adolescents with autism spectrum disorder and insomnia. The diagram tracks participants through screening, treatment phases, and follow-up periods." />
  <figcaption>Figure 1. Study enrollment and participant flow for a long-term follow-up trial of prolonged-release melatonin (PedPRM) in children and adolescents with autism spectrum disorder and insomnia. The diagram tracks participants through screening, treatment phases, and follow-up periods.<br>  Source: Athanasios Maras et al. "Long-Term Efficacy and Safety of Pediatric Prolonged-Release Melatonin for Insom." <em>Journal of child and adolescent psychopharmacology</em>, 2018. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/30132686/">30132686</a></figcaption>
</figure>

Related Evidence

A
Melatonin for Insomnia

Grade A · 237 studies

 A
Melatonin for Sleep Onset Difficulty

Grade A · 30 studies